Arthur Rosner, MD
Otolaryngology · Rochester Hills, MINPI 1790781573
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.3%. Reporting peaked in 2019 at $2,904 and has fallen 69.8% since, to $877 in 2025. Among otolaryngology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $50.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$3K
- Acelrx Pharmaceuticals, Inc.$2K
- Stryker$2K
- Aerin Medical Inc.$917
- Harmony Biosciences LLC$781
- Jazz Pharmaceuticals Inc.$670
- plus $3K from 18 others
What the payments were for
- Consulting fees$2,25019%
- Speaking & faculty fees$7506%
- Travel & lodging$2,86824%
- Food & beverage$6,06051%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 16 | $2,664 |
| Acelrx Pharmaceuticals, Inc. | 2 | $2,264 |
| Stryker | 40 | $2,158 |
| Aerin Medical Inc. | 8 | $917 |
| Harmony Biosciences LLC | 31 | $781 |
| Jazz Pharmaceuticals Inc. | 27 | $670 |
| Optinose US, Inc. | 21 | $456 |
| Sanofi | 17 | $444 |
| Axsome Therapeutics, Inc. | 27 | $416 |
| Regeneron Healthcare Solutions, Inc. | 19 | $401 |
| GSK | 12 | $227 |
| Acclarent, Inc | 3 | $152 |
| AstraZeneca | 3 | $146 |
| Amgen | 1 | $34 |
| Neurent Medical Limited | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Fortovia Therapeutics, Inc. | 2 | $25 |
| Resmed Corp | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Davol Inc. | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINUVA$2,276
- DSUVIA$2,250
- PROPEL$2,016
- SCOPIS ENT$1,378
- VIVAER STYLUS$750
- RHINAER STYLUS$750
- XYWAV$125
- SUNOSI$122
- TEZSPIRE$116
- Vivaer RF Stylus$116
How this compares
$11,962 in reported general payments places this provider in the 90th percentile of 257 otolaryngology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $43,791 |
| XhanceFluticasone Propionate | 11 | $18,209 |
| Fluticasone Propionate | 189 | $4,410 |
| Azelastine Hcl | 108 | $3,929 |
| Ipratropium Bromide | 59 | $2,506 |
| Prednisolone Acetate | 14 | $1,271 |
| Ofloxacin | 40 | $700 |
| Sulfacetamide Sodium | 15 | $505 |
| Omeprazole | 54 | $498 |
| Cefdinir | 27 | $378 |
| ValacyclovirValacyclovir Hcl | 16 | $328 |
| Famotidine | 24 | $245 |
| Amitriptyline Hcl | 22 | $205 |
| Tramadol Hcl | 59 | $161 |
| Prednisone | 70 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $456 | $18,20911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 otolaryngology providers in Michigan.
Other otolaryngology in Rochester Hills
- Charles BoydBirmingham$825K
- Jack KartushFarmington Hills$225K
- Robert StandringSouthfield$217K
- Robert StachlerWest Bloomfield$174K
- Giancarlo ZulianiBloomfield Hills$61K
- Lamont JonesDetroit$52K
- Gregory WolfAnn Arbor$46K
- Paul HoffAnn Arbor$44K
- Susan GaretzAnn Arbor$40K
- John CraigDetroit$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.